Document Detail


Fluoxetine therapy in obese diabetic and glucose intolerant patients.
MedLine Citation:
PMID:  1338388     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A double-blind placebo-controlled trial was conducted, involving 97 obese diabetic and glucose intolerant patients receiving either 60 mg fluoxetine daily (47 patients) or a placebo (50 patients); a similar calorie-restricted diet was prescribed to all patients. Weight loss was significantly higher in the fluoxetine-treated patients, whose diabetic status improved. Drop-out rate was not significantly different for both groups of patients.
Authors:
M Kutnowski; J C Daubresse; H Friedman; J Kolanowski; G Krzentowski; A Scheen; L Van Gaal
Related Documents :
19372358 - Surface anatomy as a guide to vertebral level for thoracic epidural placement.
18493558 - The assessment of esophagogastroduodenoscopy tolerance a prospective study of 300 cases.
1994758 - Patient-controlled sedation during epidural anesthesia.
19448208 - Same-patient reproducibility of state entropy: a comparison of simultaneous bilateral m...
19140878 - Complement split products c3a and c4a in chronic lyme disease.
20034098 - Diagnostic utility of daytime salivary melatonin levels in smith-magenis syndrome.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Multicenter Study    
Journal Detail:
Title:  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity     Volume:  16 Suppl 4     ISSN:  0307-0565     ISO Abbreviation:  Int. J. Obes. Relat. Metab. Disord.     Publication Date:  1992 Dec 
Date Detail:
Created Date:  1993-04-27     Completed Date:  1993-04-27     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9313169     Medline TA:  Int J Obes Relat Metab Disord     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  S63-6     Citation Subset:  IM    
Affiliation:
Hôpital Universitaire Brugmann, Department of Internal Medicine, ULB, Brussels, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Glucose / metabolism
Diabetes Mellitus / blood,  drug therapy*,  physiopathology
Double-Blind Method
Female
Fluoxetine / adverse effects,  therapeutic use*
Glucose Tolerance Test
Hemoglobin A, Glycosylated / analysis
Humans
Hyperglycemia / blood,  physiopathology*
Insulin / blood
Male
Middle Aged
Obesity / blood,  drug therapy*,  physiopathology
Placebos
Weight Loss
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/Hemoglobin A, Glycosylated; 0/Placebos; 11061-68-0/Insulin; 54910-89-3/Fluoxetine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients.
Next Document:  A randomized double-blind clinical trial of fluoxetine in obese diabetics.